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Diabetic nephropathy (DN) is a major cause of morbidity and premature mortality of4
diabetic patients. Several genetic susceptibility loci have been documented, but no5
causative variants implying novel pathogenetic mechanisms have been elucidated.6
Methods7
We carried out whole-genome sequencing of a cohort of Finnish type 1 diabetes (T1D)8
siblings discordant for the presence (case) or absence (control) of DN, where the9
controls have had diabetes without complications for 15-37 years. We analyzed and10
annotated variants at genome, gene, and single nucleotide variant levels. We then11
replicated the associated variants, genes and regions in the FinnDiane replication cohort12
which includes 3,531 unrelated Finns with T1D.13
Results14
We observed protein-altering variants and an enrichment of variants in regions15
associated with the presence or absence of DN. Replication in FinnDiane confirmed16
variants in both regulatory and protein-coding regions. We also observed that DN17
associated variants, when clustered at the gene level, are enriched in a core protein18
interaction network of podocyte. These genes include protein kinases, i.e. protein kinase19
C isoforms epsilon and iota, and protein tyrosine kinase 2.20
Conclusion21
We carried out a comprehensive analysis of a DN cohort with T1D patients discordant22
for kidney disease and report our findings on a website http://dnc.systems-genetics.net/.23
The results shed light on variants and genes potentially causative or protective for DN.24




With the increase in the incidence of diabetes worldwide, complications like diabetic28
nephropathy, retinopathy, neuropathy, skin ulcers and amputations, have become a29
major global health and socio-economic threat. In addition to intensive blood glucose30
control1, the only drugs providing a significant delay in progression of diabetic31
nephropathy (DN) are angiotensin-converting enzyme inhibitors (ACE-I) or32
angiotensin receptor blockers (ARB) that reduce intraglomerular pressure and efferent33
arteriolar vasoconstriction2. The molecular pathogenesis of DN is still poorly34
understood. Hyperglycemia, a major risk factor for complications, causes accumulation35
of toxic glucose derivatives, such as methylglyoxal, that bind covalently to the side36
chains of amino acids, particularly arginine and lysine, and also methionine and37
cysteine3; 4. Hyperglycemia alone is not sufficient to trigger the development of38
complications, as only 30-40 % of T1D individuals develop diabetic microangiopathy1;39
5; 6. Independent familial studies have shown a trend of family aggregation of DN in40
different populations7; 8, suggesting a genetic predisposition to DN. At least four41
metabolic pathways have been implicated in the development of complications: polyol42
flux, increased the formation of advanced glycation end products, hyperactivity of the43
hexosamine pathway and activation of protein kinase C (PKC) isoforms4; 9; 10.44
Genome-wide association studies (GWAS) and candidate gene approaches have45
identified several potential genomic loci for DN susceptibility11, but no variants with a46
major effect on the risk of complications have been found, suggesting that DN is47
modulated by a number of variants in genes that cooperate within complex pathways.48
It is intriguing, however, that several independent genome-wide linkage analysis49
studies carried out on American Caucasians, Pima Indians, African Americans, and50
Finns, have identified the same DN susceptibility locus on chromosome 3q12-15. The51
complex interaction between genetics, risk factors such as hyperglycemia and52
environmental components makes it more challenging to find specific genes for DN53
using genetic association studies. To that end, it could be advantageous to search for54
DN susceptibility genes in populations such as Finns, a uniquely homogeneous55
European population16 with the world’s highest incidence of T1D17; 18. With a56
combination of founder effects and genetic isolation, the population has accumulated57
rare genetic traits referred to as the “Finnish Disease Heritage”19. In addition, Finland58
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has a good public health care system, including nationwide disease and treatment59





In order to search for DN susceptibility genes, we have assembled a cohort of Finnish65
T1D siblings with extreme phenotypes regarding the presence (case) or absence66
(control) of DN. This discovery cohort contained 76 T1D sibling pairs discordant (DSP)67
for DN, and three T1D families with three siblings (in total 80 cases and 81 controls).68
The samples came from two sources: the Finnish National Institute of Health and69
Welfare diabetes collections, as described elsewhere15, and the Finnish Diabetic70
Nephropathy (FinnDiane) study20. Furthermore, 3,531 unrelated T1D individuals71
(1,344 cases and 2,187 controls) (Figure 1a) from FinnDiane were used for replication72
of findings made in the discovery cohort. The main clinical characteristics of patients73
in the discovery cohort are summarized in Table 1.74
75
Study subjects76
The discovery cohort consisted of sib-pairs and small families, whereas the replication77
cohort consisted of unrelated individuals, all having T1D. The renal status was based78
on the albumin excretion rate (AER) in a 24 hr urine collection or the79
albumin/creatinine ratio (ACR) in a random, spot urine collection. The presence of end-80
stage renal disease (ESRD) was defined according to whether patients were undergoing81
dialysis or had received a kidney transplant. DN was defined by (1) persistent82
macroalbuminuria (AER>300 mg/24 hr or ACR>30 mg/mmol) in two of three83
consecutive measurements or the presence of end-stage renal disease; and (2) the84
absence of clinical or laboratory evidence of nondiabetic renal or urinary-tract disease.85
Control status was defined by normoalbuminuria (AER < 30 mg/24 hr or ACR < 386
mg/mmol) despite duration of diabetes for at least 15 years [range 15-37]. In the87
discovery cohort, all study subjects had been diagnosed with T1D for at least 15 years,88
with the age at onset<30 years; in the replication cohort, age at diabetes onset was ≤4089
years, with insulin dependence within one year after the diagnosis of diabetes (or age90
at diabetes onset ≤15 years). Controls in the replication cohort had minimum diabetes91
5
duration of 15 years. The replication cohort included 2,187 controls with normal AER92
and 1,344 cases with macroalbuminuria and ESRD.93
94
Ethical permits95
All diabetic patients gave written, informed consent to participate in the study and the96
Ethical Committee of the Finnish National Public Institute, the Ethical Committee of97
the Helsinki and Uusimaa Health District, and Karolinska Institutet approved the98
protocol for the study. The transgene manipulation in zebrafish was approved by the99
local ethical committee (the North Stockholm district court).100
101
Whole Genome Sequencing (WGS)102
WGS was carried out on the discovery cohort using both Illumina HiSeq 2000 and103
Complete Genomics platforms. In order to evaluate the quality of the two different104
sequencing methods, we sequenced four discordant sib pairs with both platforms and105
compared the difference of the called variants across different platforms. The methods106
used for sequence alignment, quality control, variant calling and single nucleotide107
variant (SNV) annotation can be found in the Supplementary Methods.108
109
Bioinformatics approaches for Whole Genome Sequencing (WGS) analysis110
To fully utilize WGS data, we performed the association analysis with DN at three111
levels (Figure 1b): (A) genome-level analyses to study hot-spots of mutations and112
SNVs impacting regulatory regions; (B) gene-level aggregation tests to identify genes113
with DN-predisposing (or protecting) variants; and (C) SNV-level focusing on the114
PAVs (Protein-Altering Variants) present only in cases or only in controls and115
therefore, potentially causal or protective for DN. Each level of analysis uses different116
criteria for statistical significance; a brief summary of the statistical models and criteria117
used in each analysis is reported in Table 2. A global snapshot of all DN-associated118
variants and replicated in the FinnDiane cohort is provided in Figure 2.119
120
Association test for single nucleotide variants (SNVs)121
For each SNV, we tested the association with DN using four genetic models: (1) case-122
dominant, (2) case-recessive, (3) control-dominant and (4) control-recessive21. To this123
aim, we employed the Firth logistic regression method that accounts for rare variants124
and provides bias-reduction in case of small sample size analysis22; 23 to assess the125
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significance of the association (P-value) in the discovery, replication and combined126
cohorts. Odds ratio (OR) and P-values for association were calculated using Firth's bias-127
reduced penalized-likelihood logistic regression method, and was implemented in the128
R package logistf24. The association test results were used to select SNVs for (B) gene-129
level test, and (C) SNV level test. The criteria for selection are different in (B) and (C),130
see details below.131
132
(A) Genome level analysis133
To identify genomic regions with frequent variants associated with DN in the 76 DSP,134
we set out to (1) identify regions that are significantly recurrently mutated (recurrently135
mutated regions or RMRs) compared to the distribution of mutations across the genome136
and (2) test each region for significant overrepresentation of mutations in DN cases or137
controls. For (1) we followed the method proposed by Weinhold et al25. Briefly, all138
mutations located within 50 base pairs (bp) of each other were merged using139
BEDTools26 into hot-spot clusters and this procedure was repeated until no cluster was140
found within 50 bp of another cluster. The optimal cluster size was determined141
empirically given the observed distribution of mutations and their distance in the142
genome (data not shown). Clusters with less than three mutations were removed. For143
each cluster, a P-value was calculated using the negative binomial distribution, taking144
into account the length of the candidate hot-spot region, the number of mutations in the145
cluster and the background mutation rate (average mutation rate per sample) for the146
cluster that was estimated using the genome-wide expectation. The candidate hot-spot147
regions were selected for further analyses based on their P-value for significance and148
using a stringent Bonferroni correction for the number of regions tested (Figure S1).149
To identify RMR associated with DN (called DN-RMR), for each region we counted150
the number of mutations found in DN cases or controls and carried out Fisher’s Exact151
Test (FET) to assess whether a mutation was overrepresented in either cases or controls.152
The Benjamini-Hochberg false discovery rate (FDR) correction to account for the153
number of regions tested by FET was applied to identify DN-RMR at the genome-wide154
level. For details of the analyses performed on transcription factor binding sites (TFBS),155




We applied the adjusted SKAT test for familial data of dichotomous traits (F-SKAT27)159
on the multi-sib cohort (N=161). SNVs within a gene region were clustered together160
for the analysis. The gene region included variants in upstream 1000 bp, downstream161
1000 bp, 3’ UTR, 5’ UTR, intron and exon. Only the protein-altering variants in the162
exonic region were included, i.e. nonsynonymous, stop-gain, stop-loss and splice site163
variants in RefSeq. We performed the gene-level aggregation test on three different sets164
of variants: (i) SNVs nominally associated with a case-control phenotype in the165
discovery cohort (OR>1.5 and nominal P<0.05, Firth test) irrespective of their MAF166
(Minor Allele Frequency); (ii) all SNVs with MAF<0.01 irrespective of their167
association with DN in discovery cohort; (iii) all SNVs with MAF<0.05 irrespective of168
their association with DN in discovery cohort. Genes that reached significance in the169
F-SKAT analysis (nominal F-SKAT P<0.01) have been annotated for functional170
enrichment test using Enrichr28.171
172
(C) SNV level analysis173
To select significant SNVs for replication, we focused on the SNVs that are PAV174
(missense, nonsense, stop-loss, splicing site) or located in an exonic region in non-175
coding RNAs (ncRNAs). SNVs present only in cases or only in controls in dominant176
(³3 individuals) or recessive (³1 individual) were selected for replication in the177
FinnDiane cohort. For analysis of replication, an association test, as described above,178
was carried out on the discovery (T1D sib-pairs discordant for nephropathy, N=152),179
replication (FinnDiane, N=3,531) and combined cohorts (discovery plus replication,180
N=3,683). Methods for power calculation for SNVs association tests are described in181
Supplementary Methods.182
183
Analysis of replication cohort184
Genome-wide genotyping was performed on the Illumina HumanCoreExome Bead185
arrays 12-1.0, 12-1.1, and 24-1.0. The arrays include a core set of genome-wide variants186
plus an extensive set of exome variants. Data processing and quality control have been187
described earlier29. The genotype data were imputed with Micmac3 using the 1000188
Genomes reference panel (Phase 3, version 5). SNVs with poor quality (R2<0.3) were189
removed from analysis. Samples overlapping with the discovery cohort were excluded.190
Candidate SNVs were extracted from the GWAS imputation data and the number of191
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genotypes were counted for controls and cases based on the most likely genotypes using192
SNPTest.193
To evaluate the false positive rate of replication at the SNV level, we performed194
an empirical test in 3 steps: (1) select a random set of SNVs from discovery PAVs; (2)195
test association on this random set, and count the number of significant variants196
(OR>1.5, P<0.05); (3) repeat the steps 10,000 times to assess the false positive rate.197
For gene level replication, we could not apply F-SKAT to FinnDiane data, since that198
replication cohort does not contain familial data. Instead, we used SKAT30 (Sequence199
Kernel Association Test) on the same SNV set (if found in FinnDiane) as we used for200
F-SKAT in the discovery cohort. For replication in the genome level DN-RMR test, we201
extracted all SNVs within the RMR regions defined by tests of the discovery cohort,202
and tested enrichment of variants in cases or controls for each region using two-tailed203
FET, then corrected by Bonferroni P<0.01.204
205
RESULTS206
Variants detected by whole genome sequencing (WGS)207
We evaluated the sequencing quality by sequencing four sib pairs with both Complete208
Genomics and Illumina HiSeq 2000 platforms. The concordance rate across the two209
platforms for all eight individuals was 98.8% (Table S1a-c).210
WGS of the discovery cohort revealed 12 million SNVs (Table S2) and >6211
million short insertions and deletions (indels) (Table S3). Here, we focused on genetic212
variants functionally associated with the DN phenotype, i.e. variants affecting gene213
regulatory elements and/or coding regions.214
215
Genome-level analysis216
We analyzed the complete genome sequences of the 76 T1D discordant sibling pairs to217
systematically identify genomic regions that are recurrently mutated and218
overrepresented in the DN cases or controls (i.e., individuals with T1D but without219
DN). A similar approach has been employed in studies of genome-wide noncoding220
regulatory mutations in cancer25, and is based on (i) genome-wide “hot-spot” mutation221
analysis to identify small regions with frequent (recurrent) mutations and analysis of222
clusters of recurrent mutations, (ii) DNA variants impacting TFBS, and (iii) annotated223
regulatory regions (e.g., promoters and enhancers).224
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For the genome-wide “hot-spot” mutation analysis, we identified a total of225
850,137 RMR. Each RMR represents a genomic locus enclosing a cluster of variants226
within 50 bp of each other, and genome-wide RMRs have a median size of 436 (min 4227
to max 37,433) bp. Each identified RMR is significantly recurrently mutated compared228
to a random distribution of mutations across the genome (Bonferroni corrected229
P<3.7×10-5, Figure S1).230
We first tested whether these RMRs are significantly over-represented in DN231
cases or in controls. After correcting for the number of total RMRs analyzed, we232
detected 732 RMRs that are over-represented in either DN cases or in controls at FDR233
<5%, thereby identifying a set of RMRs associated with diabetic nephropathy234
(hereafter, DN-RMR) (Figure 3a and Table S4). 141 of these DN-RMRs (19.26%)235
were replicated in the FinnDiane cohort (Bonferroni P<0.01). 458 (63%) DN-RMRs236
are intergenic, whereas 274 (37%) overlap with 194 annotated genes. When compared237
with the whole set of RMRs identified at the genome-wide level in the discovery cohort,238
the DN-RMRs more frequently overlap with exons, introns, 3’ and 5’ UTRs, enhancers239
and gene promoter regions (Figure 3a). This suggests that DN-associated clusters of240
mutations are more likely to impact exons and regulatory regions than the RMRs that241
are not associated with DN. The genes overlapping with DN-RMRs are significantly242
enriched for several canonical KEGG pathways relevant to the pathobiology of DN243
(P<0.01), including ECM-receptor interaction, focal adhesion and type I diabetes244
(Figure 3b). These pathways have several genes in common, suggesting that the245
identified DN-RMRs affect multiple genes interacting across overlapping functional246
pathways (Figure 3b). Interestingly, COL4A1 and COL4A2, which encode the most247
prominent non-GBM collagens were shown to be associated with DN, as previously248
reported31,32. Both genes were enriched for variants in intronic regulatory regions, but249
their possible role in the pathogenesis of DN remains obscure, especially as no exonic250
mutations were different between cases and controls in these genes in the discovery251
cohort.252
As the second genome-level approach, in order to investigate the potential253
regulatory impact of DN-associated variants, we retrieved and annotated254
experimentally derived TFBS data from a large repository of ChIP-seq data255
representing DNA binding data for 237 transcription factors (TFs)33. Within each TFBS256
region, we tested whether there was a significant over-representation of variants in DN-257
ascertained cases or in controls (Figure 3c). Overall, we found more variants impacting258
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TFBS in controls than in cases, and in some instances these variants are present only in259
controls and across multiple families. By pooling results for TFs over their260
corresponding TFBSs, we identified 40 TFs with significantly different variant261
frequencies between cases and controls (Benjamini-Hochberg corrected P<0.05) and 6262
(out of 20 TFs for which genotype data was available in the replication cohort) were263
replicated in FinnDiane (Bonferroni P<0.01) (Table S5). The 40 TFs were enriched for264
pathways relevant to the pathophysiology of DN (Figure 3d). These include the265
epidermal growth factor receptor (EGFR)-dependent endothelin signaling (implicated266
in the development and progression of renal fibrosis and hypertrophy of the glomerular267
basement membrane), which has been proposed for targeting by endothelin antagonist268
therapy in DN34. We also found the structurally related transmembrane receptors269
belonging to the receptor tyrosine kinase superfamily (e.g. ErbB1) that are involved in270
the development and progression of DN35. Of note, variants in ERBB4 have previously271
been suggested to be associated with DN18; 36, even though the causal variants were not272
identified.273
The third genome-level analysis approach, was to study annotated regulatory274
regions in the genome (gene promoters and enhancers) which are derived from the275
FANTOM5 database37 and were further supported by ENCODE38 histone modification276
data, and to test whether variants in these regions were significantly overrepresented in277
DN cases or controls. We found significant enrichment (FDR<0.05) for DN-associated278
variants in 270 promoter regions (±1kb around the annotated gene transcription start279
site (TSS)), 68 (25.2%) were replicated in the FinnDiane cohort (Bonferroni P<0.01)280
(Table S6a). We also found significant enrichment (FDR<0.05) for DN-associated281
variants within ±1kb of 44 predicted enhancers (Table S6b). DN-associated variants in282
five enhancers were replicated in the larger FinnDiane cohort (Bonferroni P<0.01). We283
further prioritized candidate genes within these replicated enhancers using data related284
to topologically associated domains, epigenetic regulation, and transcriptome analysis285
of DN in human39 (Table S7).286
Not surprisingly, in a few cases distinct genome-level analyses prioritized the287
same gene locus. For instance, ALOX5, encoding arachidonate 5-lipoxygenase (a288
member of the lipoxygenase gene family regulating metabolites of arachidonic acid),289
was found to overlap with an intragenic DN-RMR spanning 4,724 bp and has DN-290
associated variants in two predicted enhancers and in its annotated promoter region,291
suggesting potential enhancer-promoter interaction40 (Figure 3e). A role for292
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lipoxygenase inhibitors in DN has been proposed in the rat41 and 12-lipoxygenase is293
increased in glucose-stimulated cultured mesangial cells and in kidney of rat DN294
model42. Furthermore, it has been shown that 5-lipoxygenase contributes to295
degeneration of retinal capillaries in a mouse model of diabetic retinopathy, suggesting296
a proinflammatory role of 5-lipoxygenase in the pathogenesis of DN43.297
298
Gene-level analysis299
To investigate the aggregated gene-level contribution of multiple SNVs, we used300
the F-SKAT framework (Sequence Kernel Association Test adjusted for familial data301
of dichotomous traits)27. We tested different sets of SNVs that were aggregated at the302
gene level (see Methods). We only found a few genes that reached the nominal303
significance level of P<0.05 by testing on the rare variants (Table S8), and found no304
associations with any relevant functional pathways or networks. Alternatively, we first305
identified 28,237 SNVs (within 3,745 genes) that were nominally associated with DN306
susceptibility or protection (OR >1.5, P<0.05). Then we gathered all DN-associated307
SNVs that were within upstream 1000 bp, downstream 1000 bp, UTR regions, intronic308
and PAVs, and tested their accumulative effect on each gene. We found 206 genes that309
reach a significance level of P<0.01 in the F-SKAT analysis (Table S9a-b).310
To investigate the potential function of the SNVs in the 206 genes detected by F-311
SKAT, we analyzed these SNVs using a recent expression quantitative trait locus312
(eQTL)44 dataset from the glomerulus and tubulointerstitium of subjects with nephrotic313
syndrome. We found that these F-SKAT significant genes are more likely to be under314
cis-acting regulation in the glomeruli of nephrotic syndrome patients than genes with315
non-significant F-SKAT (OR=3.84, P=2.2×10-16). This suggests that the SNVs316
contributing to the gene-level association with DN (detected by F-SKAT) may exert317
their pathological function by regulating gene expression in the kidney. We then used318
Enrichr28 to test for functional enrichment in the 206 genes identified by F-SKAT, and319
observed the only significant enrichment for protein-protein interactions in the320
podocyte network expanded by STRING (XPodNet45), (22/808 genes, enrichment321
P=0.0045, Wikipathways 2016). The F-SKAT associated genes within the core322
XPodNet are shown in Figure 4a and Table S10. The genes in this sub-network of323
XPodNet are enriched for several pathways, including focal adhesion and insulin324
signaling (Figure 4b and Table S11). The top candidate gene from the F-SKAT test is325
the protein kinase C epsilon gene (PRKCE) (F-SKAT P=0.0004), with multiple intronic326
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DN-associated SNVs that overlap with predicted regulatory regions (Figure 4c, Table327
S9b). Protein kinases PRKCE, PTK2 (F-SKAT P=0.0037) and PRKCI (F-SKAT328
P=0.0085) are part of a “core protein-interaction network” representing proteins329
essential for podocyte function. These genes are particularly interesting as PKCs have330
been implicated in the pathogenesis of DN10. However, specific inhibitors for those331
three PKCs have not yet been developed to our knowledge.332
Furthermore, we tested the 206 genes which were found to be significant using333
F-SKAT in the replication cohort. This replication is limited by the less numerous334
SNVs in FinnDiane compared with the discovery cohort (2,316 out of 3,755 SNVs),335
which also does not include family data. Therefore, we applied SKAT using only the336
same SNVs used by F-SKAT in the discovery cohort. This is a rather stringent337
replication approach, as it tests for both the genes and the specific SNVs that were found338
to be associated with DN in the discovery cohort. Out of the 206 genes tested, only 120339
genes were found with at least one F-SKAT SNV, and nine genes passed the nominal340
criteria P<0.05, including a protein kinase gene PTK2 (Table S9c). The replicated341
genes are highlighted in Figure 2.342
343
Analyses of protein-altering variants (PAVs)344
It has been estimated that about 85% of mutations underlying Mendelian diseases reside345
in coding sequences or at exon-intron borders46; 47. Numerous reports have described346
rare but highly penetrant exon mutations in Mendelian disease48,49, and it is likely that347
such mutations also frequently contribute to complex disease phenotypes. Our initial348
exon variant analyses have focused on 53,449 PAVs (nonsynonymous, stop-gain, stop-349
loss and splice site variants Table S2) that were exclusively found in cases or controls350
in the 76 T1D DSP and are associated with DN-susceptibility or DN-protection. The351
PAVs were tested for association with DN in the FinnDiane cohort using a recessive352
disease model for the homozygous variants detected in ³1 cases/controls in the353
discovery cohort and by a dominant model for the heterozygous SNVs detected in ³3354
cases/controls in the discovery cohort. The 47 PAVs identified in the recessive model355
were replicated in FinnDiane (P<0.05, OR>1.5). By using a permutation based-strategy356
(see Methods), we estimated the probability that these 47 PAVs are replicable by357
chance alone is only 2.3%. However, the false positive rate in the dominant model is358
estimated to be high (Figure S2). Therefore, only candidate SNVs that were replicated359
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in the recessive model are reported (top SNVs in Table 3, and in full in Table S12).360
Some of the top-replicated PAVs are within genes that have previously been linked to361
renal disease, implying a potential role in DN, e.g. mutations in WDR73 have been362
reported to be responsible for late-onset steroid-resistant nephrotic syndrome50. We also363
studied the gene function of ABTB1, where we found the only case-only homozygous364
mutation that is truncating the protein. Zebrafish knockout of the gene displayed a365
phenotype that is specific for kidney damage (Supplementary Method, Supplementary366
Results, Figure S3).367
Hyperglycemia causes an increase in intracellular ROS that leads to increase in368
glucose derivatives, such as methylglyoxal, that readily react with amino groups of369
protein amino acid residues, particularly arginine, lysine, cysteine and methionine51.370
Here, PAVs altering amino acid codons to arginine were found to be significantly less371
represented in the set of mutations detected in controls only as compared with all PAVs372
(OR = 0.66, 95% CI [0.43-0.97], P=0.03, Figure S4). No other classes of mutations373
leading to individual amino acid(s) substitution showed significant over-374
representation/depletion in either cases or controls.375
376
Power Calculation377
To estimate the statistical power for detecting association in our sibship discovery378
cohort, we used a method described by Li et.al52. We estimated the power assuming379
different levels of penetrance (Table S14a). Our sample size of 76 DSP reaches >80%380
power to detect significant associations (P<4.11x10-9) for rare variants with high381
penetrance (penetrance=90%, MAF=0.01). Furthermore, we estimate the power for the382
replication study. Similar to a previous report18, our replication cohort (N=3,531)383
reaches at least 80% power detect common variants with high OR (OR=2, MAF=0.05384
in the dominant model; OR=5, MAF=0.2 in the recessive model).385
386
DISCUSSION387
To the best of our knowledge, this is the first study where WGS has been applied in a388
search for genomic variants specifically associated with the presence or absence of DN389
in T1D patients. The challenge with finding susceptibility genes for diabetes390
complications is that one searches for mutations that only cause complications if the391
individual has hyperglycemia. We assembled a unique discovery cohort of T1D siblings392
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from the highly homogeneous Finnish population and replicated key findings in a larger393
cohort of unrelated T1D Finns. This enabled a direct comparison of whole-genome394
sequences in individuals with extreme phenotypes, i.e. T1D with progressive DN on395
one hand, and siblings with no complications for at least 15 years [range 15-37] on the396
other. The results provide a unique catalogue of DNA variants in Finns.397
We have developed a comprehensive panel of multiple bioinformatic approaches398
to detect genetic pre-deposition of DN in the discovery sib cohort. The SNVs approach,399
which evaluates PAVs that are present only in cases or controls, focuses on the potential400
protein function in DN. The kernel test (F-SKAT) prioritizes genes with multiple401
associated variants within the gene region, and hypothesizes that the accumulated402
burden leads to malfunction of the gene. The genomic approach includes variants in403
other genome regions and could potentially detect functionally important regions.404
These approaches identified different individual variants, genes and regulatory regions405
that are potentially involved in DN susceptibility.406
Although the discovery cohort only consisted of 161 individuals with T1D,407
together with the FinnDiane replication cohort, we show that they can provide enough408
power to identify and replicate potential causative and protective mutations for DN.409
Here, the use of discordant T1D sib-pairs for DN has been pivotal to increase power to410
identify variants associated with DN susceptibility of protection.411
We have also studied the replication of candidates and report candidates with412
robust signals for each analysis approach. However, while the replication of SNVs is413
commonly used for GWAS where it applies on the same loci, the replication for414
statistical tests which involve multiple loci, i.e. RMR, F-SKAT and TFBS have415
limitations that need to be taken into consideration. For replication of F-SKAT in416
FinnDiane, about one-third of F-SKAT SNVs cannot be found by array genotyping plus417
imputation. Thus, the number of replicable genes is limited (120/206), and within each418
gene, SNVs are also less represented. Additionally, the use of a different statistical419
model (SKAT versus F-SKAT) might also introduce a bias in the replication test. The420
constraints caused by limited genotypes in the replication cohort also apply to the RMR421
and TFBS replications. The data-driven detection of RMR requires comprehensive422
SNV data (i.e. WGS data). Using a panel of predefined genotyped SNPs (i.e. SNP array423
data), even if the panel is large and supported by imputation, might introduce a424
considerable bias in the replication of DN-associated RMRs.425
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The analyses of the discovery cohort led to the identification of several novel DN426
candidate genes in Finns, including PRKCE, PTK1, PRKCI, ABTB1, and ALOX5 as427
discussed above. The significant association of three protein kinase genes with DN is428
intriguing, as the large PKC protein family has long been associated with diabetes429
complications4; 10. Several clinical trials have been carried out for the treatment of DN430
with Ruboxistaurine, a compound that inhibits PRKC-b53. This suggests that431
hyperglycemia-driven PKC activation, particularly that of the b isoform, may underlie432
endothelial dysfunction. In the present study, we identified two novel isoforms of433
protein kinase C family (i.e. epsilon and iota) that have not been previously linked to434
DN. The results strongly support and extend previous hypotheses that protein kinases,435
especially protein kinase C family, play a role in the pathogenesis of DN, and could be436
attractive novel targets for the development of PKC inhibitors for DN treatment.437
DN is a disorder characterized by hyperglycemia, which can lead to non-438
enzymatic glycation of amino acids and formation of advanced glycation end products439
in both intracellular and extracellular proteins4; 9; 54. It can be speculated that glycation440
of amino acids in functionally important regions of the protein can affect functionality441
of the protein or promote their degradation3. Amino acids that are most prone to become442
non-enzymatically glycated by methylglyoxal and other carbonyls, are arginine, and to443
a lesser extent lysine55, cysteine and methionine4; 9. Our study highlighted mutated444
arginine codons as being of special interest when considering mutations that can cause445
pathogenic non-enzymatic glycation of proteins and consequent development of DN.446
Previously reported genes/regions associated with DN were not strongly447
replicated in our discovery cohort (Table S15), suggesting that different sets of448
loci/variants contribute to the pathogenesis of DN. However, despite the scarce449
replication of previous loci in our cohort, we report the identification of variants/genes450
in functional pathways relevant to the pathobiology of DN, many of which have been451
previously reported (e.g. EGFR-dependent endothelin signaling34 and PodNet45).452
Overall, we have performed a comprehensive study on the genetics of a unique453
T1D Finnish cohort of siblings discordant for nephropathy using WGS data. Although454
the sample size is relatively small and the association test for SNV cannot reach the455
genome-wide significance (P<4×10-9), efforts were made to optimize the test model to456
fit for the specific sibship cohort, and the top-listed SNVs were replicated (when457
applicable) in larger Finnish cohort. Novel potential DN susceptibility genes and458
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regulatory variants are promoted in hope to merit further investigation in other459
populations and animal models.460
461
Availability of genome analysis results462
All genetic association data presented here are made freely accessible via463
http://dnc.systems-genetics.net.464
465
DESCRIPTION OF SUPPLEMENTAL DATA466
Supplemental Data include supplementary methods, results, web resources used in the467
study, five figures and fifteen tables.468
469
DISCLOSURES470
P-H G has received investigator-initiated research grants from Eli Lilly and Roche, is471
an advisory board member for AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim,472
Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestle,473
Novartis, Novo Nordisk and Sanofi; and has received lecture fees from AstraZeneca,474
Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme,475
Medscape, Novartis, Novo Nordisk, PeerVoice and Sanofi.476
477
ACKNOWLEDGEMENTS478
The work was supported by grants from the Novo Nordisk Foundation, Knut and Alice479
Wallenberg, Söderberg's, and Hedlund's Foundations, the Swedish Medical Research480
Council, the Swedish Foundation for Strategic Research, Sigrid Juselius Foundation,481
Folkhälsan Research Foundation, the Wilhelm and Else Stockmann Foundation, the Liv482
och Hälsa Foundation, Helsinki University Central Hospital Research Funds (EVO),483
JDRF (17-2013-7 (DNCRI)), European Foundation for the Study of Diabetes (EFSD)484
Young Investigator Research Award funds, and the Academy of Finland (Grants 38387,485
46558, 275614, 299200, and 316664). This work has also been supported by Singapore486
grants from NMRC grant (NMRC/STaR/0010/2012) and the Singapore National487
Medical Research Council (NMRC/OFLCG/001/2017). We are grateful to the488
physicians, nurses, and researchers in the FinnDiane study group and at each center489
participating in the collection of patients. We thank Leena Ollitervo and Maire Jarva490
for technical assistance on DNA extraction. We also acknowledge Dr. Jaakko491
Tuomilehto for the original collection of samples. The computational analyses were492
17
performed on resources provided by SNIC through Uppsala Multidisciplinary Center493
for Advanced Computational Science (UPPMAX) under Project b2013027, and the494
High-Performance Computing Cluster in Duke-NUS computational center.495
496
18




Supplementary Table 1. Comparison of DNA sequencing quality using the Illumina
and Complete Genomics platforms.
Supplementary Table 2. Annotation of SNVs and indels identified in 161 genomes in
the Discovery cohort by RefSeq.
Supplementary Table 3. Frameshift-causing small insertions and deletions (indels)
found in DN cases-only or controls-only individuals of the Finnish T1D DSP discovery
cohort
Supplementary Table 4. Recurrently mutated regions (RMR) significantly
overrepresented in DN cases or controls (FDR<5% in discovery cohort) and replication
in FinnDiane cohort.
Supplementary Table 5. Transcription factor binding site (TFBS) impacted by DN-
mutations.
Supplementary Table 6. Enhancer (S6a) and promoter (S6b) region with mutations
overrepresented in DN cases or controls (FDR<0.05 in discovery cohort) and
replication statistics in FinnDiane cohort.
Supplementary Table 7. Enhancers replicated in FinnDiane cohort and gene
prioritization
Supplementary Table 8a. Genes associated with DN by F-SKAT analysis (P<0.01).
Supplementary Table 8b. Details on the DN-associated SNVs used in the F-SKAT
analysis.
Supplementary Table 9a. F-SKAT test results on rare SNVs with MAF<0.01. Only
top genes with P-value<0.1 are reported.
Supplementary Table 9b. F-SKAT test on SNVs with MAF<0.05. Only top genes
P<0.1 are reported.
Supplementary Table 9c. Replication of F-SKAT significant (P<0.01) genes in
FinnDiane cohort.
Supplementary Table 10. PodNet genes detected by F-SKAT (P<0.01)
Supplementary Table 11. Functional enrichment test (KEGG pathways) on the core
genes within the XPodNet network in Figure 4.
Supplementary Table 12. Protein-altering SNVs replicated in FinnDiane cohort
(combined P-value < 0.05, OR>1.5), in each genetic model.
Supplementary Table 13. Non-coding RNA SNVs replicated in FinnDiane cohort
(combined P-value < 0.05, OR>1.5), in each genetic model.
Supplementary Table 14a. Power estimation of discovery cohort (76 discordant
sibling pairs) on the whole genome level of significance (12 million, P<4.11x10-9) of
case-only and control-only variants. Power estimation based different penetrance.
Supplementary Table 14b. Power estimation of replication cohort (2,187 controls and
1,344 cases) with genome wide significance level (P<5x10-8) with one-stage study
design.
Supplementary Table 15. Test previously reported SNVs (Single Nucleotide Variants)
in discovery cohort. SNVs were downloaded from GWAS Catalog.
19
Supplementary Figures
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Figures and Tables
Figure 1.  Cohorts and study design. (a) Cohorts used in the search for DN susceptibility
genes in Finnish type 1 diabetes (T1D) patients: the genomes of a total of 76 sib pairs
concordant for T1D but discordant for diabetic nephropathy (DSPs) were subjected to whole
genome sequencing (WGS). Additionally, T1D siblings from three families with three siblings
(Multiple Siblings, MS) with or without diabetic nephropathy (DN) were included in the
sequencing analyses. The control siblings (81) have had diabetes for at least 15 years [range
15-37] without developing DN, and have never been on ACE-I or ARB medication for kidney
disease. The case siblings (80) have had overt proteinuria, been on dialysis, received a kidney
transplant or have died from kidney complications. (b) Multi-level strategy used to analyze the
WGS data from Finnish T1D individuals with or without diabetes complications.
Figure 2.  Schematic view of DNA variants and regions in Finnish T1D sib pairs
discordant for diabetic nephropathy (DN). The circos plot consists of multiple layers,
each of which represents a bioinformatic analysis approach and its significant outcomes
in the discovery cohort. From the outside to the center; Cytoband as a genome location
reference. DN-associated protein altering variants (PAVs) that are replicated in FinnDiane are
highlighted. PAVs that are highly enriched in cases are marked in red while green in controls.
In the second layer, genes with highly enriched cluster of DN-associated variants that has been
prioritized by F-SKAT are depicted in the orange circle, and those passing the stringent
replication are marked by their names. From the third layer, regions of recurrent mutations that
are associated with case or control (DN-RMR) are shown in the light green circle, followed by
promoters (±500 bp from a promoter annotated CAGE cluster according to FANTOM5) in light
blue, enhancers (±500 bp from an enhancer annotated CAGE cluster according to FANTOM5)
in light purple, and Transcription Factor Binding Sites (TFBS) in light red. The details of the
statistical models and the call of significance of association for each approach are listed in
Table 2.
Figure 3. Genome-wide analysis of variants in recurrently mutated regions and
transcription factor binding sites associated with diabetic nephropathy in the discovery
cohort. (a) Annotation of recurrently mutated regions (RMR) with respect to overlapping gene
regulatory elements; relative frequencies have been calculated with respect to each group: all
RMR (white) and DN-associated RMR (red). (b) Significantly over-represented KEGG
pathways comprise common genes overlapping with DN-RMR. The relationships between
genes overlapping with DN-RMR and KEGG pathways is depicted as a network graph, wherein
the outer circle comprises genes and inner circle comprises the pathways. (c) Schematic
representation of genome-wide analysis of variants occurring in transcription factor binding
sites (TFBSs), that were derived from 668 ChIP-Seq datasets (see Methods). (d) We identified
40 transcription factors (TFs) with significantly different variant frequencies between cases and
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controls, in the TFBSs, which were significantly enriched for pathways relevant to the
pathophysiology of DN. For the top ten enriched KEGG pathways, the known relationships
(edges) between transcription factors (inner circle) and the KEGG pathways (outer circle) are
depicted as a network graph. (e) We found an enrichment of variants in cases in the promoter
and enhancer regions (±1kb) of the ALOX5 gene locus. Enhancers and promoter regions were
retrieved from FANTOM5 and cross-checked with chromHMM, whereas other gene
annotations were obtained from RefSeq (see Methods).
Figure 4. Genes identified by F-SKAT analysis within the podocyte network. (a) Graphical
representation of the core podocyte network that includes the genes associated with DN by F-
SKAT analysis in the discovery cohort. Node color indicates the statistical significance (P-
value) of the F-SKAT test. White color nodes indicates podocyte network genes not detected
in the current study. (b) The F-SKAT associated genes within the podocyte network are
enriched (adjusted P<0.05) for several pathways; top six pathways and contributing genes are
reported. Full functional enrichment results are reported in Table S6. (c) Details on the protein
kinase C epsilon (PRKCE) gene that showed the highest association with DN (by F-SKAT) and
location of the intronic SNVs associated with DN. For each SNV, the association with DN is
reported by odds ratio tested in either a recessive or dominant model. Full statistics and
regulatory information on the SNVs are reported in Table S4b.
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Table 1. Clinical characteristics of the Finnish type 1 diabetes patient discovery cohort. Data
are reported as range or mean ± standard deviation.
Cases Controls
N1 (male %) 80 (61.3) 81 (46.9)
T1D
Duration2 (years) Range 21-38 Range 15-37
Age at onset (years) 11.6±8.1 16.6±11.3
Blood pressure (mmHg)
Systolic 149.2±23.1 (n=60) 135.4±15.3 (n=59)








HbA1c (%) 9.0±2.0 (n=70) 8.4±1.4 (n=57)
BMI (kg/m2) 26.3±5.0 (n=63) 26.4±3.9 (n=57)








ESRD3 (%) 46.3 0
1 N, number of subjects
2 Duration till year 2017
3 ESRD, end-stage renal disease
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Table 2. Summary of test results from the genomic, gene and single variants levels of
data analysis on 76 DSP.






















































































































































*Variant clustering method proposed by Weinhold et al.
**FDR: Benjamini-Hochberg False Discovery Rate.
***F-SKAT: Sequence kernel association test for familial data with dichotomous traits.
§Case-only or control-only: ³3 heterozygous individuals in only case/control in dominant model; ³1 homozygous
individual in only cases/control in recessive model.
¥PAV: Protein-Altering Variants, i.e. nonsynonym, stopgain, and stoploss.
#MAF: Minor Allele Frequency
N.A. Not Available.
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Table 3. Top protein-altering variants replicated cohort with criteria P-value < 0.05, OR>1.5 in FinnDiane cohort.











WDR73 WD repeat domain 73 rs72750868 0.044 0.076 T|B D->G 2|0 2.516 0.002 2.635 0.001
TPPP2 tubulin polymerization promoting protein familymember 2 rs9624 0.160 0.148 D|D R->L 1|0 3.284 0.003 3.395 0.002
UBR7 ubiquitin protein ligase E3 component n-recognin 7 rs2286653 0.113 0.147 T|B A->T 1|0 3.549 0.008 3.744 0.005
ATP10D ATPase phospholipid transporting 10D rs34208443 0.077 0.141 T|B P->T 1|0 1.654 0.009 1.648 0.009
ANO9 anoctamin 9 rs114405390 0.015 0.027 T|B T->A 1|0 4.089 0.012 4.407 0.007
SIGIRR single Ig and TIR domain containing rs117739035 0.016 0.029 D|D S->Y 1|0 3.600 0.013 3.847 0.008
SFT2D1 SFT2 domain containing 1 rs11551053 0.111 0.077 T|B I->V 1|0 3.041 0.015 3.208 0.009
HKR1 HKR1, GLI-Kruppel zinc finger family member rs2921563 0.098 0.054 T|D R->H 1|0 5.717 0.017 6.402 0.009
KRT32 keratin 32 rs2604956 0.046 0.071 T|D D->E 1|0 2.153 0.020 2.210 0.015
C6orf118 chromosome 6 open reading frame 118 rs17852379 0.103 0.073 T|D G->E 1|0 2.547 0.026 2.673 0.018
PPP4R1 protein phosphatase 4 regulatory subunit 1 rs329003 0.041 0.073 .|B I->V 2|0 2.999 0.027 3.474 0.009
ANKRD26 ankyrin repeat domain 26 rs12572862 0.067 0.036 T|B V->L 1|0 8.157 0.029 9.595 0.013
PKHD1L1 polycystic kidney and hepatic disease 1 rs117037399 0.005 0.019 T|P G->V 1|0 8.157 0.029 9.592 0.013
CSMD1 CUB and Sushi multiple domains 1 rs34337712 0.021 0.069 T|B Q->H 1|0 1.865 0.033 1.899 0.027
C6orf10 chromosome 6 open reading frame 10 rs7775397 0.019 0.060 T|P K->Q 1|0 1.546 0.036 1.546 0.035
TMEM176A transmembrane protein 176A rs10378 0.128 0.139 D|D L->F 0|1 0.383 0.004 0.366 0.002
C4orf51 chromosome 4 open reading frame 51 rs10008599 0.077 0.098 D|B D->N 0|1 0.180 0.007 0.167 0.004
SIGMAR1 sigma non-opioid intracellular receptor 1 rs1800866 0.217 0.184 T|B Q->P 0|2 0.432 0.010 0.403 0.005
CPTP ceramide-1-phosphate transfer protein rs150672559 0.005 0.007 T|B R->H 0|1 0|9 0.013 0.000 0.008
NEFH neurofilament heavy polypeptide rs5763269 0.151 0.182 D|B P->L 0|1 0.493 0.014 0.473 0.009
TNFRSF14 TNF receptor superfamily member 14 rs2234167 0.114 0.130 T|B V->I 0|1 0.472 0.018 0.451 0.012
TBC1D9 TBC1 domain family member 9 rs13118702 0.010 0.020 T|B E->K 0|1 0.135 0.021 0.122 0.012
UNC93A unc-93 homolog A rs2235197 0.110 0.109 .|. W->* 0|4 0.514 0.022 0.463 0.007
TYR tyrosinase rs1042602 0.123 0.252 .|D S->Y 0|5 0.630 0.025 0.581 0.007
ATAD3B ATPase family, AAA domain containing 3B rs139902189 0.078 0.076 D|P C->T 0|1 0.324 0.028 0.302 0.018
TEX101 testis expressed 101 rs35033974 0.041 0.084 D|D G->T 0|3 0.511 0.032 0.466 0.013
AVEN apoptosis and caspase activation inhibitor rs61729120 0.007 0.016 D|D G->T 0|2 0.231 0.033 0.198 0.014
ZNF844 zinc finger protein 844 rs76842919 0.026 0.060 D|B A->G 0|1 0.231 0.033 0.211 0.020
ZNF844 zinc finger protein 844 rs8102258 0.119 0.095 T|B T->C 0|1 0.231 0.033 0.211 0.020
OR6X1 olfactory receptor family 6 subfamily X member 1 rs12364099 0.077 0.122 D|B C->A 0|1 0.537 0.035 0.515 0.023
Case/control only protein-altering SNVs that remain significant (odds ratio >1.5, p<0.05) after replication in the FinnDiane cohort (1,344 cases, 2,187 controls). Only the top 15 protein-altering SNVs
detected in the recessive model (case or control only) are listed here (full results are reported in Table S12).
Minor Allele Frequency (MAF) in general population is annotated from 1000 Genome (1000G) project and ExAC. Odds ratios and p-values were assessed using the Firth’s Penalized Likelihood
logistic regression (see Methods). *Odds ratio, or number of homozygous carriers of the variant. The potential effect of a variant in the protein is predicted by SIFT and Polyphen2 (PP2).
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